Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Department of Medicine, Dinfectome Inc., Nanjing, China.
Front Cell Infect Microbiol. 2024 Nov 14;14:1456407. doi: 10.3389/fcimb.2024.1456407. eCollection 2024.
The aim of this study was to compare the detection performance of mNGS against that of conventional tests (CT) in patients suffering from infection after kidney transplantation.
A total of 138 samples from 85 kidney transplant patients with acute or chronic infections were simultaneously analyzed using mNGS and CT from July 2021 to August 2023.
Compared with CT, mNGS demonstrated a higher sensitivity (95.96% vs. 27.27%) but lower specificity (48.72% vs. 84.62%) in pathogen detection. Moreover, mNGS exhibited significant advantages in detecting mixed and rare infections. The pathogens commonly identified in kidney transplant patients were severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), followed by Pneumocystis jirovecii and Cytomegalovirus (CMV). mNGS guided the precise clinical diagnosis in 89.13% of cases and assisted in altering therapeutics from empirical antibiotic approaches to personalized plans in 56.10% of cases, including treatment escalation (40.65%), initiation (11.38%), drug adjustment (3.25%), and de-escalation (0.81%).
Our study demonstrated the superior detection performance of mNGS and its significant clinical value. This reflected the great potential of mNGS as a complementary clinical detection technology for kidney transplant patients.
本研究旨在比较宏基因组下一代测序(mNGS)与常规检测(CT)在肾移植后感染患者中的检测性能。
2021 年 7 月至 2023 年 8 月,对 85 例发生急性或慢性感染的肾移植患者的 138 份样本同时进行 mNGS 和 CT 分析。
与 CT 相比,mNGS 在病原体检测中的灵敏度(95.96%比 27.27%)更高,但特异性(48.72%比 84.62%)更低。此外,mNGS 在检测混合和罕见感染方面具有显著优势。肾移植患者常见的病原体依次为严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)、卡氏肺孢子虫和巨细胞病毒(CMV)。mNGS 指导了 89.13%的临床精准诊断,并在 56.10%的病例中帮助将经验性抗生素治疗转变为个体化方案,包括治疗升级(40.65%)、起始治疗(11.38%)、药物调整(3.25%)和降级(0.81%)。
本研究显示了 mNGS 的优越检测性能及其重要的临床价值。这反映了 mNGS 作为肾移植患者的一种补充临床检测技术具有巨大潜力。